Effect of carbazilquinone on lymphoid leukemia L-1210.
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007939:Leukemia L1210; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D011809:Quinones / Q000627:therapeutic use*; D013997:Time Factors; D014228:Triaziquone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001389:Azirines; D008937:Mitomycins; D011809:Quinones; D003520:Cyclophosphamide; D014228:Triaziquone; D008727:Methotrexate